Articles

ABOUT AUTHORS:
Vishwa Deepak Kumar*, Abhishek Sharma, Rajneesh Mishra, Kanchan Sharma
B.Pharmacy, 2nd year
Department of Pharmacy, IEC group of institutions,
Greater Noida (U.P) INDIA, Pin- 201301
*vdkumar.iec@gmail.com

ABSTRACT
For the past few decades, there has been a considerable research interest in the area of drug delivery using particulate delivery systems as carriers for small and large molecules. Particulate systems like nanoparticles have been used as a physical approach to alter and improve the pharmacokinetic and pharmacodynamic properties of various types of drug molecules. They have been used in vivo to protect the drug entity in the systemic circulation; various polymers have been used in the formulation of nanoparticles for drug delivery research to increase therapeutic benefit, while minimizing side effects. Here, we review various aspects of nanoparticle formulation, characterization, effect of their characteristics and their applications in delivery of drug molecules and therapeutic genes. Nanoparticles are the preparations having size in nanometers.

ABOUT AUTHOR:
Verma Siddharth
Sri Ram Institute of Technology,
ITI Jabalpur M.P. 482003
luckyverma84@gmail.com

ABSTRACT
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that may affect many tissues and organs, but principally attacks synovial joints. The process produces an inflammatory response of the synovium (synovitis) secondary to hyperplasia of synovial cells, excess synovial fluid and the development of pannus in the synovium. Various treatments are available. Non-pharmacological treatment includes physical therapy, orthoses, occupational therapy and nutritional therapy. Analgesia (painkillers) and anti-inflammatory drugs including steroids are used to suppress the symptoms, while disease-modifying antirheumatic drugs (DMARDs) are often required to inhibit or halt the underlying immune process and prevent long-term damage. In recent times, the newer group of biologics has increased treatment options.

About Authors:
Madhulika Kabra¹, Pramod Khatri²*, Neerja Gupta^3
1 Professor of Pediatrics,
^2,3 Department of Pediatrics,
AIIMS Hospital, India
*pramodsinghkhatri@gmail.com

INTRODUCTION
As pharmaceutical companies are progressing rapidly in manufacturing prefilled syringes to meet patients needs, one area where their convenience is appreciated, is by patients who need to self-inject. The first prefilled syringe-based reusable auto-injector was launched in the 1990s by Glaxo Smith Kline for treating migraine.

About author:
Priya Diwedi
M.Pharm
Bhopal institute of technology and science-pharmacy, Bhopal (M.P)
Priya.diwedi07@gmail.com

About Author:
Akshay Rajgaria
Kanak Manjari Institute of Pharmaceutical Sciences
akshaykrish2007@gmail.com

ABSTRACT
Transdermal drug delivery system (TDDS) provides a means to sustain drug release as well as reduce the intensity of action and thus reduce the side effects associated with its oral therapy. Transdermal drugs are self contained, discrete dosage form. Transdermal Drug Delivery System is the system in which the delivery of the active ingredients of the drug occurs by the means of skin. Skin is an effective medium from which absorption of the drug takes place and enters the circulatory system. Various types of transdermal patches are used to incorporate the active ingredients into the circulatory system via skin. The patches have been proved effective because of its large advantages over other controlled drug delivery systems.

About Authors:
Bhuvanesh Sharma¹*, Bhupendra Vyas¹, Yuvraj Singh Sarangdevot¹, Pankaj Sharma¹, Abhishek Sharma¹.
¹Dept. of Quality Assurance, B.N. College of Pharmacy,
Udaipur (Raj) 313001
*bhuvan110@gmail.com

About Author:
Shanta Mishra
MBA at IILM-Institute For Higher Education
New Delhi, India
Sonni.m3@gmail.com